tony_montello2003 • Jan 23, 2014 10:22 AM
ACTC to release Interim Top Line Data 1/24/2014, 1. 0 Safety issues, 2. progression of the disease halted
in all patients in phase 1 trials in US and UK for both AMD/SMD.
3. Majority patients not only progression of the disease halted in treated eye but also gain Visual Acuity.
4. FDA grants breakthrough therapy designation for AMD.
5. UK grants Treatment IND for SMD with patient treatment to begin as early as June 2014.
Let it be written,
Dr. Tony Montello just left the building.)
****JV partner announcement next week*********